when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Rare Disease · news · pharmadog

← back to Rare Disease

News · Rare Disease

856 stories

Jul 8, 26Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversalbiopharma dive

Jul 8, 26Another big premium hike on the horizonstat

Jul 8, 26Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefitsstat

Jul 7, 26Oberland pours up to $400M into MeiraGTx eye gene therapiesbiopharma dive

Jul 7, 26STAT+: Compass says depression drug has long-lasting benefitsstat

Jul 7, 26Vertex to acquire Crinetics in $10B foray into endocrine disease drugsbiopharma dive

Jul 7, 26STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and morestat

Jul 7, 26Vera Therapeutics wins FDA nod for closely watched kidney disease drugbiopharma dive

Jul 6, 26STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A boomsstat

Jul 2, 26A PureTech startup banks $180M for a new IPF drugbiopharma dive

Jul 2, 26STAT+: Halfway into the year, biotech is boomingstat

Jul 2, 26Opinion: Teens are turning to chatbots for mental health help. We need rules to keep them safestat

Jul 2, 26STAT+: A year after distressed buyout, what’s become of Bluebird Bio?stat

Jul 1, 26FDA Approves First Gene Therapy for Young Children with Sickle Cell Diseasefda press

Jul 1, 26BridgeBio gets funding for drug launch; United buys into cell therapybiopharma dive

Jul 1, 26Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M dealbiopharma dive

Jul 1, 26STAT+: More signs that GLP-1s may help with peripheral artery diseasestat

Jul 1, 26FDA says Zyn can market its pouches as safer than cigarettesstat

Jul 1, 26STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watchstat

Jul 1, 26Opinion: What Ebola and Marburg are teaching us about the next pandemicstat

Jun 30, 26FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patientsfda press

Jun 30, 26Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot programbiopharma dive

Jun 30, 26These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.biopharma dive

Jun 30, 26Top FDA gene and cell therapy regulator to step downbiopharma dive

Jun 30, 26Opinion: Florida is the first state to require EKGs for high school athletes. It’s a mistakestat

Jun 29, 26FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturingfda press

Jun 29, 26Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone diseaseendpoints

Jun 29, 26Theravance, after clinical setbacks, agrees to $929M buyoutbiopharma dive

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive

Jun 26, 26Alkermes’ incoming CEO has a plan to outplay Lilly and Takedabiopharma dive

← prevpage 22 of 29next →